ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Piperidynes Take A New Number

Organic Synthesis: The first example of a 3,4-piperidyne opens up a new path to preparing nitrogen heterocycles as drug candidates

by Stephen K. Ritter
April 13, 2015 | APPEARED IN VOLUME 93, ISSUE 15

09315-scicon-piperidyne.jpg

Nitrogen-containing heterocycles make up about 60% of FDA-approved small-molecule drugs, with piperidines being the most common. With the aim of synthesizing new functionalized piperidines, UCLA’s Neil K. Garg, Kendall N. Houk, and coworkers wondered if the unusual molecule 3,4-piperidyne could be generated and used as a synthetic building block. Although aromatic 2,3- and 3,4-pyridynes are common and aliphatic 2,3-piperidynes are known, a 3,4-piperidyne has not been reported before now. The researchers first developed a three-step synthesis of a carboxybenzyl-protected trimethylsilyl-triflate piperidine derivative as a starting material. Treating this compound with cesium fluoride generates the reactive 3,4-piperidyne in situ. By including a nucleophile or cycloaddition partner in the mixture, the UCLA team can trap the 3,4-piperidyne as a piperidine derivative. The team used a computational model to predict and explain regioselectivities and made an array of new functionalized piperidine products (J. Am. Chem. Soc. 2015, DOI: 10.1021/jacs.5b01589). The silyltriflate precursor has proven so useful that it is in the process of being commercialized by Sigma-Aldrich.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment